Sector
PharmaceuticalsOpen
₹472Prev. Close
₹480Turnover(Lac.)
₹191.06Day's High
₹495.35Day's Low
₹465.752 Week's High
₹63052 Week's Low
₹375.05Book Value
₹170.08Face Value
₹10Mkt Cap (₹ Cr.)
627.53P/E
60.36EPS
7.98Divi. Yield
0.21Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 12.71 | 13.78 | 12.22 | 12.22 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 196.49 | 180.02 | 135.82 | 122.14 |
Net Worth | 209.2 | 193.8 | 148.04 | 134.36 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 110.14 | 117.34 | 111.5 | 82.45 |
yoy growth (%) | -6.13 | 5.23 | 35.23 | 22.56 |
Raw materials | -66.87 | -72.95 | -67.65 | -49.2 |
As % of sales | 60.71 | 62.17 | 60.67 | 59.67 |
Employee costs | -8.79 | -9.29 | -9.05 | -6.65 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 16.75 | 16.6 | 13.9 | 6.35 |
Depreciation | -2.51 | -2.49 | -2.05 | -1.92 |
Tax paid | -4.26 | -4.34 | -3.78 | -1.19 |
Working capital | -1.38 | -8.09 | 38.28 | 6.51 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -6.13 | 5.23 | 35.23 | 22.56 |
Op profit growth | 10.23 | 7.79 | 49.71 | 119.69 |
EBIT growth | 3.74 | 5.29 | 73.66 | 146.26 |
Net profit growth | 1.85 | 21.22 | 95.97 | 973.02 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 179.31 | 140.87 | 115.45 | 112.72 | 125.5 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 179.31 | 140.87 | 115.45 | 112.72 | 125.5 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 2.33 | 2.46 | 1.72 | 0.75 | 1.94 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,698.35 | 129.24 | 4,07,155.15 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,549.7 | 71.05 | 1,47,295.24 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,444.25 | 25.07 | 1,16,664.33 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183.9 | 59.03 | 1,07,673.27 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,458.1 | 52.42 | 1,01,358.17 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non Executive Director
Sanjay Bansal
Chairman (Non-Executive)
Rahul Bishnoi
Non Executive Director
Ashwani Kumar Sharma
Independent Director
Harish Pande
Non Executive Director
S K Singh
Independent Director
Arun Kumar
Company Sec. & Compli. Officer
Parul Choudhary
Independent Director
Sumita Dwivedi
Non Executive Director
Vimal Kumar Shrawat.
Independent Director
Sangeeta Bishnoi
Independent Director
Ravi Kumar Bansal
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Medicamen Biotech Ltd
Summary
A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets. The Company has presence in 40+ countries. Its offerings include Finished Dosage Forms (FDFs) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market. MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan). The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.The Bhiwadi unit has ultra modern production facilities incorporating latest state of the art technology with a combination of technically qualified personnel and hardworking workforce. In Haridwar unit, the company manufactures Non-Betalactum preparations including tablets, capsules, oral liquids and ointments & creams.Medicamen Biotech Limited was incorporated in December, 1993 and started their operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries.The vast distribution network
Read More
The Medicamen Biotech Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹493.55 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Medicamen Biotech Ltd is ₹627.53 Cr. as of 01 Apr ‘25
The PE and PB ratios of Medicamen Biotech Ltd is 60.36 and 2.78 as of 01 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Medicamen Biotech Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Medicamen Biotech Ltd is ₹375.05 and ₹630 as of 01 Apr ‘25
Medicamen Biotech Ltd's CAGR for 5 Years at -2.21%, 3 Years at -10.16%, 1 Year at 23.79%, 6 Month at -15.71%, 3 Month at -2.31% and 1 Month at 2.80%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.